Correlations between parameters in uroflowmetry and histological compositions in patients with benign prostatic hyperplasia

Urologia Internationalis

Volumn 57, Issue 1, 1996, Pages 48-50

  Ishigooka, Manabu ^a   Hayami, Shinsuke ^a   Hashimoto, Tohru ^a   Suzuki, Yasuhiro ^a   Sasagawa, Isoji ^a   Nakada, Teruhiro ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Morphometric analysis; Prostatic adenoma; Symptom score; Uroflowmetry

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOLOGY; HUMAN; MALE; MICTURITION; MORPHOMETRICS; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SCORING SYSTEM; SYMPTOM; UROFLOWMETRY;

EID: 0030017995     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282876     Document Type: Article

References (18)

1. Caine M: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986:136:1-4.
2. Monda JM, Oestcrling JE: Medical treatment of benign prostatic hyperplasia: 5a-Reductase inhibitors and a-adrenergic antagonists. Mayo Clin Proc 1993:670-679.
3. Lepor H, Gup DI, Baumann M, Shapiro E: Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991:67:493-498.
4. Bartsch G, Muller HR, Oberholzer M, Rohr HP: Light microscopic stcrcological analysis of the normal human prostate and benign prostatic hyperplasia. J Urol 1979:122:487-491.
5. Siegel YI, Zaidel L, Hammel I, Korczak D: Morphometrical evaluation of benign prostate hyperplasia. Eur Urol 1990:8:71-73.
6. Shapiro E, Hartanto V, Lepor H: Quantifying the smooth muscle content of the prostate using double-immunocnzymatic staining and color of the prostate using double-immunoenzy-matic staining and color assisted image analysis. J Urol 1992:147:1167-1170.
7. Costa P, Robert M, Sarrazin B, Mottet N, Nav-ratil H: Quantitative topographic distribution of epithelial and mesenchymal components in benign prostatic hypertrophy. Eur Urol 1993; 24:120-123.
8. Marks LS, Treiger B, Dorey FJ, Fu YS, DeKer-nion JB: Morphometry of the prostate. I. Distribution of tissue components in hyperplastic glands. Urology 1994;44:486-492.
9. Shapiro E, Haratanto V, Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992: 21:297-307.
10. Nishimoto K, Iimori H, Ikemoto S, Nayahara N: Criteria for differentiation of normal and abnormal uroflowmctrograms in adult men. Br J Urol 1994:73:494-497.
11. Barry MJ, Fowler FJ, O'leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockctt ATK, The measurement committee of the American Urological Association: The American urological association symptom index for benign prostalic hyperplasia. J Urol 1992:148: 1549-1557.
12. Nitti VW, Kim Y, Combs AJ: Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia Neurourol Urodyn 1994:13:521-529.
13. Bosch RJIH, Griffiths DJ, Blom JHM, Schroeder FH: Treatment of benign prostatic hyperplasia by androgen deprivation: Effects on prostate size and urodynamic parameters. J Urol 1989:141:68-72.
14. Stoner E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994:43: 284-294.
15. Smith HR, Memon A, Smart CJ, Dewbury K: The value of permixon in benign prostate hypertrophy. Br J Urol 1986;58:36-40.
16. Keane PF, Timoney AG, Kicly E, Williams G, Stamp G: Response of the benign hypertrophied prostate to treatment with 1.HRH analogue. Br J Urol 1988:62:163-165.
17. Wilson JD: The pathogenesis of benign prostatic hyperplasia. Am J Med 1980;68:745-756.
18. Nording J: Definition of prostatic urethral obstruction. Urol Res 1994:22:267-271.